Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Antimicrobial Resistance

    Launch of New Antiobiotic Test Company

    By Global Biodefense StaffApril 9, 2014
    Share
    Facebook LinkedIn Reddit Email

    Researchers from the The University of Manchester and Plymouth University Peninsula Schools of Medicine and Dentistry have formed a new company, Spectromics, to commercialize rapid diagnostics for antimicrobial susceptibility testing.

    The technology will allow doctors to determine the most effective drug to be prescribed for each patient, bringing a personalized medicine approach to the widespread use of antibiotics.

    Resistance to antibiotics is exacerbated by the current practice of issuing “best guess” prescriptions without knowing whether the patient actually has a bacterial infection, and whether that particular infection may be resistant to the drug being prescribed.

    To run tests today to determine whether a drug is required and which is most effective takes days in a microbiology lab. The Spectromics technology will allow a doctor to run a 10 minute test which will indicate if an antibiotic is required, and if so, which one. The test will comprise of a small instrument and a cartridge into which the sample is added.

    The formation of Spectromics is the result of three years of research by Professor Roy Goodacre and Dr. Mathew Upton, from each of the universities cited, respectively. Both are Directors of the company.

    Over the next three years Spectromics will develop the commercial system for the first application. This will be for urinary tract infection which is the most prevalent bacterial infection affecting human health. Following this, other test specific cartridges for other clinical applications will follow.

    Neil Butler, CEO of Spectromics commented: “I have been the CEO from formation of two other companies in the past, Vivacta and Oxford Biosensors, and worked in Point-of-Care diagnostics for fifteen years. What really excites me about Spectromics is the compelling need for a diagnostic that guides antibiotic treatment at the point-of-prescription. This technology is very differentiated as nothing else comes close to our test turnaround time. We are planning to raise significant investment, so that we can build the organisation rapidly, which in turn will bring the commercial system to market ASAP. This product was needed yesterday and we are going to make this technology the answer to the global call for a solution to antimicrobial stewardship.”

    “The lack of new antibiotics, that has caused a 30 year discovery void, is alarming as our established drugs have a growing resistance making them ineffective in treating infections,” said Stephen France of UMIP, the University of Manchester’s agent for Intellectual Property commercialisation. “There are solutions to this problem: new antibiotics, and better stewardship of the ones we have, and we believe that both solutions are required for an effective remedy of the problem. When we saw the speed of this technology we knew it was a winner and this why we didn’t hesitate to build a business to exploit it fully.”

    Antimicrobials MRSA
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleRapid, Broad Countermeasures Sought Against Mystery Infections
    Next Article Chikungunya Poised to Invade the Americas

    Related Stories

    EPA Developing AMR Risk Framework for Antibacterial and Antifungal Pesticides

    September 29, 2023

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023

    Biomarkers for Detection of Exposure to Nitrogen Mustards

    September 20, 2023

    Mass Spec for Rapid Detection of Biological Warfare Agents

    September 15, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    Oct 17
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Dispensing and Administration of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.